Rectal Cancer
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab, Cetuximab, or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)
- Details
ClinicalTrials.gov ID:
NCT04485013
Diagnosis Type:
NA
USOR Number:
- Address
,
P: